 Long term surveillance studies using a drug eluting stent DES may help elucidate mechanisms responsible for death, myocardial infarction, and late stent thrombosis risks not observed during controlled pre-market trials. This study will evaluate XIENCE V Everolimus Eluting Coronary Stent System EECSS performance in the real world when used by a broad group of physicians at a variety of health care facilities. Consequently, this protocol will include all consecutively enrolled patients in India who consent to participate and receive the XIENCE V EECSS, which is expected to represent the range of clinical use during commercialization. 